Anaplastic Thyroid Cancer


Journal of Thyroid Disorders & Therapy offers the most comprehensive and reliable information pertaining to the latest developments in the field. The Journal also believes in advancing new hypotheses and opinions by means of its high quality Reviews, Perspectives, and Commentaries. Thus, the content published in the journal is original and comprehensive.

Anaplastic Thyroid Cancer (ATC) is a rare entity, well known for its aggressive nature, rapid progression, and extraordinal poor outcome. The median survival time from the diagnosis was reported to be <6months, with frequent resistance to conventional therapeutic approaches by surgery, radiation, or chemotherapy. No standardized effective therapeutic strategy has been documented for ATC in any guidelines due to the lack of objective data on the outcomes of practical treatment.

We demonstrated the feasibility and the efficacy of weekly Paclitaxel (wPAC) for patients with ATC in our recent clinical trial. This systemic chemotherapy was effective in approximately one-fifth of the patients, showing partial responses. The adverse events were mild and manageable, and high dose intensity could be maintained for more than eight administrations of paclitaxel (80 mg/m2 ). The effect of wPAC was clearly demonstrated when it was used as a pre-operative induction treatment as had been suggested in a case series.

Journal accepts original manuscripts in the form of research articles, review articles, Clinical reviews, commentaries, case reports, perspectives and short communications encompassing all aspects of related to Thyroid for publication in open access platform. All the manuscript published are available freely online immediately after publication without any subscription charges or registration.

Those who are interested to submit the editorials or their commentaries can submit at or you can mail through this mail id as an attachments

Explore more information at Thyroid Disorders and Therapy. You can share your experiences too by publishing your novel fact findings in the Journal.

Denise Williams
Editorial Manager      
Journal of Thyroid Disorders & Therapy
E-mail id: